Abstract: The present invention arises from the discovery of an endogenous malignancy-associated catabolite characterized by (i) a molecular weight of about 135 daltons as determined by mass spectrum analysis; (ii) a UV absorption maximum at 237 nm; (iii) a 15 centimeter C18 HPLC column retention time of from about 1.00 to about 2.00 minutes as compared to a retention time at a 1 ml/minute flow rate of about 2.5 to about 3.0 minutes for an internal standard marker; (iv) containing no aromatic ring structures, containing one methyl group at the 1-position and one methyl group at the 6-position of an alpha carbon chain, and containing at least one nitrogen moiety as determined by nuclear magnetic resonance; and (v) being present in elevated amounts in the urine substantially exclusively of individuals suffering from malignant conditions.